COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING IMMUNE CHECKPOINT INHIBITOR-RESISTANT CANCER

The present invention relates to a composition for preventing, ameliorating or treating immune checkpoint inhibitor-resistant cancer, comprising, as an active ingredient, a binding molecule capable of specifically binding to leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, which is a...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Jung Ho, KIM, Beom Seok
Format Patent
LanguageEnglish
French
German
Published 18.05.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a composition for preventing, ameliorating or treating immune checkpoint inhibitor-resistant cancer, comprising, as an active ingredient, a binding molecule capable of specifically binding to leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, which is a protein present on the surface of regulatory T cells (Treg). The binding molecule specific to the Lrig-1 protein according to the present invention suppresses the function of regulatory T cells in which the Lrig-1 protein is expressed at high levels, such as regulatory T cells in tumor infiltrating lymphocytes (TIL) or activated regulatory T cells, thereby very effectively preventing a phenomenon in which the function of effective T cells is suppresses by the regulatory T cells. Accordingly, the binding molecule specific to the Lrig-1 protein can effectively prevent, ameliorate or treat immune-evasive cancer, that is, cancer with resistance to immune checkpoint inhibitors.
Bibliography:Application Number: EP20200837734